Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8TA0M)

Drug Name

N,N'-Di-acenaphthen-5-yl-guanidine Drug Info

Synonyms

CHEMBL307395; 157970-69-9; Cns 1145; 1,3-di(1,2-dihydroacenaphthylen-5-yl)guanidine; AC1L4RHN; AC1Q4SU4; Cns-1145; SCHEMBL6155294; CTK4C9538; N,N'-Bis(5-acenaphthyl)guanidine; BDBM50285278; N,N''-Di-acenaphthen-5-yl-guanidine; AKOS030602590; 1,2-bis(1,2-dihydroacenaphthylen-5-yl)guanidine

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 190902
CAS Number: CAS 157970-69-9
TTD Drug ID: DM8TA0M

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Voltage-gated calcium channel alpha Cav1.3 (CACNA1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ARC029	DMYNJHI	Alzheimer disease	8A20	Phase 3	[2]
SIPATRIGINE	DMMQ4GC	Neurological disorder	6B60	Discontinued in Phase 2	[1]
SNAP-5089	DMROJEN	Heart arrhythmia	BC65	Terminated	[3]
TH-9229	DMG1MPD	Reperfusion injury	ND56.Z	Terminated	[4]
CGS-27830	DM8TLY3	N. A.	N. A.	Terminated	[5]
PD-32577	DMBA15J	Discovery agent	N.A.	Investigative	[6]
CPU-228	DMM8FUT	Cardiac failure	BD10-BD13	Investigative	[7]
(-)-(S)-BayK8644	DMEA9KH	Discovery agent	N.A.	Investigative	[7]
CV-4093	DM983QP	Discovery agent	N.A.	Investigative	[2]
[3H](+)-isradipine	DM7QE1J	Discovery agent	N.A.	Investigative	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated calcium channel alpha Cav1.3 (CACNA1D)	TT7RGTM	CAC1D_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Synthesis and characterization of N-(acenaphth-5-yl)-N'-(4-methoxynaphth-1-yl)guanidine as a glutamate release inhibitor and potential anti-ischemic agent, Bioorg. Med. Chem. Lett. 5(19):2259-2262 (1995).
2	Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity. J Med Chem. 1989 Oct;32(10):2399-406.
3	Discovery of alpha 1a-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine. J Med Chem. 1995 May 12;38(10):1579-81.
4	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008159)
5	CGS 27830, a potent nonpeptide endothelin receptor antagonist, Bioorg. Med. Chem. Lett. 3(10):2099-2104 (1993).
6	Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
7	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 530).
8	alpha 1D (Cav1.3) subunits can form l-type Ca2+ channels activating at negative voltages. J Biol Chem. 2001 Jun 22;276(25):22100-6.